PI3K/AKT and MEK/ERK pathways targeted in new therapy for docetaxel-resistant prostate cancer

A team of researchers from the Badalona Applied Research Group in Oncology (B·ARGO) and the Urologic Tumours Unit of the Institut Català d’Oncologia (ICO) and the Germans Trias i Pujol Research Institute (IGTP) have found a new therapeutic strategy for patients with a specific subtype of metastatic prostate cancer resistant to standard chemotherapy treatment with docetaxel.

Anesthesiologist Gets 190 Years for Tampering With IV Bags Used in Surgeries

A Dallas anesthesiologist was sentenced Wednesday to 190 years in prison for injecting a nerve-blocking agent and other drugs into bags of intravenous fluid at

November 21, 2024

Updated: Alnylam delays highly-anticipated ATTR readout as it changes study design

Alnylam is making a series of changes to a closely-watched study of its ATTR amyloidosis drug vutrisiran that will delay the Phase III readout from

February 16, 2024

Guardant colon cancer test struggles to detect non-cancerous tumors, FDA says

Listen to the article 3 min This audio is auto-generated. Please let us know if you have feedback. A Food and Drug Administration advisory panel

May 22, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.